Johnson & Johnson’s TECVAYLI gains CHMP backing after 71% progression-risk reduction
AI Summary- Johnson & Johnson said CHMP recommended broader TECVAYLI use in relapsed or refractory multiple myeloma.
- Teclistamab reduced progression or death risk by 71% versus standard of care.
- MajesTEC-9 evaluated patients receiving one to three prior treatment lines.